Trexquant Investment LP purchased a new stake in Puma Biotechnology Inc (NASDAQ:PBYI) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 24,529 shares of the biopharmaceutical company’s stock, valued at approximately $1,125,000. Trexquant Investment LP owned approximately 0.06% of Puma Biotechnology as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. State of Wisconsin Investment Board grew its stake in shares of Puma Biotechnology by 3.8% in the 2nd quarter. State of Wisconsin Investment Board now owns 29,700 shares of the biopharmaceutical company’s stock valued at $1,757,000 after buying an additional 1,100 shares in the last quarter. Creative Planning grew its stake in shares of Puma Biotechnology by 30.1% in the 2nd quarter. Creative Planning now owns 5,129 shares of the biopharmaceutical company’s stock valued at $303,000 after buying an additional 1,188 shares in the last quarter. Virginia Retirement Systems ET AL grew its stake in shares of Puma Biotechnology by 7.1% in the 2nd quarter. Virginia Retirement Systems ET AL now owns 22,600 shares of the biopharmaceutical company’s stock valued at $1,337,000 after buying an additional 1,500 shares in the last quarter. NumerixS Investment Technologies Inc bought a new stake in shares of Puma Biotechnology in the 2nd quarter valued at approximately $141,000. Finally, Capital Impact Advisors LLC grew its stake in shares of Puma Biotechnology by 8.0% in the 3rd quarter. Capital Impact Advisors LLC now owns 39,209 shares of the biopharmaceutical company’s stock valued at $1,796,000 after buying an additional 2,912 shares in the last quarter. 88.01% of the stock is owned by institutional investors and hedge funds.
Several equities research analysts recently weighed in on PBYI shares. Zacks Investment Research lowered Puma Biotechnology from a “buy” rating to a “hold” rating in a report on Wednesday, November 14th. Goldman Sachs Group upgraded Puma Biotechnology from a “sell” rating to a “neutral” rating and reduced their target price for the stock from $36.00 to $28.00 in a report on Monday, November 19th. Bank of America lowered Puma Biotechnology from a “buy” rating to an “underperform” rating in a report on Friday, November 2nd. ValuEngine upgraded Puma Biotechnology from a “strong sell” rating to a “sell” rating in a report on Tuesday, October 2nd. Finally, BidaskClub lowered Puma Biotechnology from a “sell” rating to a “strong sell” rating in a report on Thursday, September 20th. Five equities research analysts have rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company’s stock. Puma Biotechnology has an average rating of “Hold” and a consensus price target of $71.18.
Puma Biotechnology (NASDAQ:PBYI) last posted its earnings results on Thursday, November 1st. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.97) by $0.60. Puma Biotechnology had a negative return on equity of 301.41% and a negative net margin of 73.45%. The firm had revenue of $62.60 million during the quarter, compared to analyst estimates of $57.94 million. During the same period in the previous year, the company earned ($1.36) EPS. The company’s revenue for the quarter was up 926.2% on a year-over-year basis. Equities analysts expect that Puma Biotechnology Inc will post -3.19 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Trexquant Investment LP Purchases Shares of 24,529 Puma Biotechnology Inc (PBYI)” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://www.com-unik.info/2018/11/30/trexquant-investment-lp-purchases-shares-of-24529-puma-biotechnology-inc-pbyi.html.
Puma Biotechnology Company Profile
Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous)).
Featured Article: Fundamental Analysis and Individual Investors
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.